Starting a company and taking it public has long been the goal of many biotechnology entrepreneurs and the venture capitalists that back them.
Now, though, with the stock market unreceptive and pharmaceutical companies desperate for new products, some small privately held biotech companies are opting for a more certain if potentially less spectacular payoff: selling themselves to larger companies.
